Product Description
EYS611, a DNA plasmid that encodes for the human transferrin protein, to benefit patients diagnosed with retinitis pigmentosa (RP), as well as other degenerative retinal diseases, including late stage, dry age-related macular degeneration and glaucoma. (Sourced from: https://www.eyevensys.com/eyevensys-receives-fda-orphan-drug-designation-for-eys611-for-treatment-of-retinitis-pigmentosa/)
Mechanisms of Action: Gene Therapy, Transferrin
Novel Mechanism: Yes
Modality: Gene Therapy
Route of Administration: Injection
FDA Designation: Orphan Drug - Retinitis Pigmentosa|Retinitis *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eyevensys
Company Location: Europe
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Retinitis Pigmentosa
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|